Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza®, the first once-daily human glucagon-like injection for the treatment of type 2 diabetes. Victoza is indicated as an addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.